When It Comes To FTC M&A Review, The Times May Be A Changin'
Executive Summary
Spark signaled in an SEC filing that its merger with Roche could be delayed into 2020, fueling more speculation that FTC is increasing scrutiny over biopharma mergers.
You may also be interested in...
Roche/Spark Acquisition: First Gene Therapy Deal Clears FTC With No Divestiture
FTC found Roche would not have incentive to delay or discontinue development of Spark's gene therapy for hemophilia A. Outcome shows deals can survive closer FTC scrutiny.
Roche/Spark Deal Clears FTC In A Sigh Of Relief For Pharma Dealmakers
US Federal Trade Commission says it conducted an "exhaustive" 10-month investigation and determined Roche would not have incentive to delay the launch of a gene therapy for hemophilia A.
FTC Vote On BMS-Celgene Acquisition Splits Over Drug Pricing
Divesting Celgene's psoriasis drug Otezla will remedy anticompetitive harm from acquisition, US Federal Trade Commission votes 3-2. Dissenting Democrat commissioners want broader review of pharma mergers.